Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma.
Heimann
David M
DM
Rosenberg
Steven A
SA
D000328:Adult; D001707:Biopsy, Needle; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007262:Infusions, Intravenous; D008297:Male; D020714:Maximum Tolerated Dose; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D012074:Remission Induction; D022562:Salmonella Vaccines / Q000008:administration & dosage*; D012486:Salmonella typhimurium / Q000276:immunology*; D012494:Sampling Studies; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D022562:Salmonella Vaccines